The Latest Data on Anti-Integrin Therapy for Patients with DME

Posted on December 1, 2017 | by Allegro Ophthalmics, LLC

In a phase 2b study, ALG-1001 showed additional efficacy in patients who had plateaued on chronic anti-VEGF therapy.

To read the full article please visit Retina Today: “The Latest Data on Anti-Integrin Therapy for Patients with DME”

Allegro Ophthalmics - From Theory to Therapy